Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias

Stefano Luminari, Maria Goldaniga, Fulvia Ceccherelli, Andrea Guffanti, Emilio Bombardieri, Raffaella Marcheselli, Lilla Cro, Mariangela Colombi, Massimo Federico, Luca Baldini

Research output: Contribution to journalArticlepeer-review


High serum Mucin-1 (sMUC-1) levels have been shown in patients with adenocarcinoma and multiple myeloma (MM). We evaluated sMUC-1 levels in 76 patients with MM, 6 with plasma cells leukaemia (PCL) and 89 with monoclonal gammopathy of undetermined significance, to establish prevalence data and verify its possible prognostic role. Of the 171 patients, 27 [16%; 95% confidence interval (CI): 10-21%] had high sMUC-1 levels compared with healthy subjects (1.5%; 95% CI: 0-4%). Elevated sMUC-1 levels in MM and PCL patients correlated with anaemia and elevated serum lactate dehydrogenase levels; these patients showed a shorter survival than those with normal sMUC-1 levels (median overall survival: 25 vs. 49 months, P = 0.003).

Original languageEnglish
Pages (from-to)772-774
Number of pages3
JournalBritish Journal of Haematology
Issue number5
Publication statusPublished - Jun 2003


  • CA15.3
  • Multiple myeloma
  • Overall survival
  • Prognostic factors
  • sMUC-1

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias'. Together they form a unique fingerprint.

Cite this